TipRanks on MSN
Jacobio Pharmaceuticals Launches Promising Study on JAB-23E73 for KRAS-Altered Tumors
Jacobio Pharmaceuticals Group Co., Ltd. (($HK:1167)) announced an update on their ongoing clinical study. Study Overview: Jacobio Pharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback